Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
August 5, 2026
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
May 28, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
May 22, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
May 21, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
May 19, 2026